Rift Valley Fever Clinical Trial
Official title:
A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Rift Valley Fever Virus (RVFV) Vaccine ChAdOx1 RVF Among Healthy Adult Volunteers in Uganda
Randomised, single blind, placebo - controlled, dose-escalation, phase I clinical trial recruiting healthy adults aged 18-50 years
This is a randomised, single blind, placebo-controlled, dose escalation, phase I clinical trial to assess the safety and immunogenicity of the candidate ChAdOx1 RVF vaccine in healthy Ugandan volunteers aged 18-50. The vaccine will be administered intramuscularly. This study will run concurrently with the first-in-human ChAdOx1 RVF trial in Oxford. Vaccination at the MRC/UVRI and LSHTM Uganda Research Unit, Masaka will only begin upon receiving a favourable opinion of Uganda's trial DSMB of the 7-day post-vaccination safety analysis of the first two lowest dose groups (ChAdOx1 RVF 5 x 10^9vp and ChAdOx1 RVF 2.5 x 10^10vp) of the trial in Oxford. Volunteers will be recruited and vaccinated at the MRC/UVRI and LSHTM Uganda Research Unit Clinical Research Centre in Masaka. There will be three study groups and a total of 30 volunteers will be enrolled (table 3). Volunteers will be recruited sequentially into Groups 1,2 and 3. Within each group, eligible volunteers will be randomly allocated to receive either ChAdOx1 RVF or placebo of 0.9% Normal Saline in a ratio of 2:1 in group 1 and 5:1 in groups 2 and 3. The DSMB will analyse the 7-day post-vaccination safety data in each group and advise on whether to proceed to the next group with a higher dose . ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00869713 -
Safety and Immunogenicity Study of Rift Valley Fever Vaccine, Inactivated
|
Phase 2 | |
Recruiting |
NCT05139524 -
RVF and Other Emerging Infectious Diseases in East and Central Africa
|
||
Recruiting |
NCT03609398 -
Phase 2 Safety and Immunogenicity Study of Rift Valley Fever Vaccine
|
Phase 2 | |
Completed |
NCT00287014 -
Rift Valley Fever in Kenya
|
N/A | |
Completed |
NCT00584194 -
Safety and Immunogenicity Study of Rift Valley Fever Vaccine
|
Phase 2 | |
Completed |
NCT04754776 -
Safety and Immunogenicity of a Candidate RVFV Vaccine (RVF001)
|
Early Phase 1 | |
Completed |
NCT00415051 -
Safety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine
|
Phase 2 |